SEC Comment Letter 0000000000-24-009025 to RIGEL PHARMACEUTICALS INC (RIGL) (CIK 0001034842) (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL) (CIK 0001034842)
Date: Aug. 7, 2024 · CIK: 0001034842 · Accession: 0000000000-24-009025
AI Filing Summary & Sentiment
File numbers found in text: 333-281230
Letter
August 7, 2024 Raul R. Rodriguez President and Chief Executive Officer Rigel Pharmaceuticals, Inc. 611 Gateway Boulevard, Suite 900 South San Francisco, California 94080 Re:Rigel Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 2, 2024 File No. 333-281230 Dear Raul R. Rodriguez: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Carlton Fleming
Show Raw Text
August 7, 2024
Raul R. Rodriguez
President and Chief Executive Officer
Rigel Pharmaceuticals, Inc.
611 Gateway Boulevard, Suite 900
South San Francisco, California 94080
Re:Rigel Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed August 2, 2024
File No. 333-281230
Dear Raul R. Rodriguez:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Carlton Fleming